<DOC>
	<DOCNO>NCT02835742</DOCNO>
	<brief_summary>Objective : Determine safety efficacy GM-CSF inhalation patient aPAP . Study Design : multi-center , randomize , double-blind , placebo- control , safety/efficacy study .</brief_summary>
	<brief_title>Pulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy Trial Japan</brief_title>
	<detailed_description />
	<mesh_term>Pulmonary Alveolar Proteinosis</mesh_term>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<criteria>1 . Age 16 year 80 year ( date registration ) . 2 . Can provide sign informed consent . 3 . Willing able comply schedule visit , treatment plan , laboratory test , study procedure specify protocol ( include shortterm hospital admission ) . 4 . Autoimmune pulmonary alveolar proteinosis diagnose HRCT biopsy and/or BAL well GMCSF antibody serum positive . 5 . PaO2 &lt; 70 mmHg 5 minute spine position room air , PaO2 &lt; 75 mmHg 5 minute spine position room air symptom ( ) include cough , sputum exertional dyspnea 1 . Diagnosed secondary hereditary pulmonary alveolar proteinosis 2 . WBC 12,000/mm3 3 . Fever 38 degree celsius 4 . Severe edema 5 . History malignant disease within recent 5 year ( apply treat case uterine carcinoma situ local basal cell carcinoma ) 6 . Complication cardiovascular disease include congestive heart failure , angina pectoris , hemorrhagic tendency , etc severe condition . 7 . Complication respiratory disease pulmonary infectious disease ( incl . pulmonary tuberculosis ) , bronchial asthma , lung fibrosis , interstitial pneumonitis , bronchiectasis , evaluation safety efficacy GMCSF therapy consider difficult . 8 . History complication infectious disease require systemic administration antibiotic , antifungal antiviral agent within recent 2 week . 9 . Treatment cytokines 10 . Pregnant possibly pregnant woman , lactate woman , woman desire become pregnant study period 11 . Patients treat wholelung lavage , repeat segmentallung lavage , rituximab within 6 month start study ( criterion apply patient 6 month elapse last lavage rituximab ) 12 . Severe liver dysfunction ( AST &gt; 100 IU/L and/or ALT &gt; 100 IU/L and/or Tbil &gt; 3.0mg/dL ) 13 . Severe renal dysfunction ( Ccr &lt; 30 mL/min , calculate CockcroftGault ( CG ) formula ) 14 . Previous experience severe unexplained sideeffects aerosol delivery kind medicinal product 15 . Treatment oral intravenous administration inhalation corticosteroid . 16 . Treatment inhale drug . 17 . Previously treat GMCSF start study . 18 . Demonstrate hypersensitivity GMCSF agent . 19 . Other patient judge inappropriate study attend physician ( e.g. , patient unlikely complete treatment uncooperative ) .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>